UA95225C2 - Модифицированный полимером фактор viii для лечения гемофилии, способ его получения - Google Patents
Модифицированный полимером фактор viii для лечения гемофилии, способ его полученияInfo
- Publication number
- UA95225C2 UA95225C2 UAA200706559A UAA200706559A UA95225C2 UA 95225 C2 UA95225 C2 UA 95225C2 UA A200706559 A UAA200706559 A UA A200706559A UA A200706559 A UAA200706559 A UA A200706559A UA 95225 C2 UA95225 C2 UA 95225C2
- Authority
- UA
- Ukraine
- Prior art keywords
- factor viii
- haemophilia
- modified
- preparation
- treatment
- Prior art date
Links
- 229960000301 factor viii Drugs 0.000 title abstract 2
- 208000031220 Hemophilia Diseases 0.000 title 1
- 208000009292 Hemophilia A Diseases 0.000 title 1
- 238000000034 method Methods 0.000 title 1
- 229920000642 polymer Polymers 0.000 title 1
- 102100026735 Coagulation factor VIII Human genes 0.000 abstract 1
- 108010054218 Factor VIII Proteins 0.000 abstract 1
- 102000001690 Factor VIII Human genes 0.000 abstract 1
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 abstract 1
- 239000002202 Polyethylene glycol Substances 0.000 abstract 1
- 125000003277 amino group Chemical group 0.000 abstract 1
- 229920000249 biocompatible polymer Polymers 0.000 abstract 1
- 229920001223 polyethylene glycol Polymers 0.000 abstract 1
- 230000002947 procoagulating effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
- A61K38/37—Factors VIII
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/02—Local antiseptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
- C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
- C07K17/02—Peptides being immobilised on, or in, an organic carrier
- C07K17/08—Peptides being immobilised on, or in, an organic carrier the carrier being a synthetic polymer
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Hematology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Toxicology (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Materials For Medical Uses (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Orthopedics, Nursing, And Contraception (AREA)
- Other Resins Obtained By Reactions Not Involving Carbon-To-Carbon Unsaturated Bonds (AREA)
Abstract
Изобретение касается мутеинов фактора VIII, которые ковалентно связаны на мутантном цистеиновом остатке с одним или более биосовместимыми полимерами, такими как полиэтиленгликоль. Конъюгаты мутеина сохраняют прокоагулянтную активность FVIII и имеют улучшенные фармакокинетические свойства.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US62727704P | 2004-11-12 | 2004-11-12 |
Publications (1)
Publication Number | Publication Date |
---|---|
UA95225C2 true UA95225C2 (ru) | 2011-07-25 |
Family
ID=36337298
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UAA200706559A UA95225C2 (ru) | 2004-11-12 | 2005-11-14 | Модифицированный полимером фактор viii для лечения гемофилии, способ его получения |
Country Status (32)
Country | Link |
---|---|
US (4) | US7632921B2 (ru) |
EP (9) | EP3243834A1 (ru) |
JP (5) | JP2008524117A (ru) |
KR (7) | KR101904630B1 (ru) |
CN (6) | CN105148287B (ru) |
AU (1) | AU2005304622B2 (ru) |
BR (2) | BRPI0517795B8 (ru) |
CA (1) | CA2586379C (ru) |
CY (3) | CY1119292T1 (ru) |
DK (3) | DK2371856T3 (ru) |
ES (4) | ES2930159T3 (ru) |
FR (1) | FR19C1031I2 (ru) |
HK (3) | HK1117875A1 (ru) |
HN (1) | HN2007015683A (ru) |
HR (2) | HRP20180481B1 (ru) |
HU (5) | HUE050542T2 (ru) |
IL (3) | IL182903A (ru) |
LT (5) | LT2371856T (ru) |
LU (1) | LUC00118I2 (ru) |
MA (1) | MA29663B1 (ru) |
MX (2) | MX2007005466A (ru) |
NL (1) | NL300989I2 (ru) |
NO (3) | NO345800B1 (ru) |
NZ (1) | NZ555032A (ru) |
PH (2) | PH12014500352B1 (ru) |
PL (3) | PL2363414T3 (ru) |
PT (4) | PT3130601T (ru) |
RU (1) | RU2423380C2 (ru) |
SI (4) | SI2363414T1 (ru) |
UA (1) | UA95225C2 (ru) |
WO (1) | WO2006053299A2 (ru) |
ZA (1) | ZA200703696B (ru) |
Families Citing this family (106)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL1615945T3 (pl) | 2003-04-09 | 2012-03-30 | Ratiopharm Gmbh | Sposoby glikopegylacji i białka/peptydy wytwarzane tymi sposobami |
WO2005012484A2 (en) | 2003-07-25 | 2005-02-10 | Neose Technologies, Inc. | Antibody-toxin conjugates |
US20080305992A1 (en) | 2003-11-24 | 2008-12-11 | Neose Technologies, Inc. | Glycopegylated erythropoietin |
US7579444B2 (en) * | 2004-06-30 | 2009-08-25 | Nektar Therapeutics Al, Corporation | Polymer-factor IX moiety conjugates |
WO2006010143A2 (en) | 2004-07-13 | 2006-01-26 | Neose Technologies, Inc. | Branched peg remodeling and glycosylation of glucagon-like peptide-1 [glp-1] |
JP5948627B2 (ja) | 2004-10-29 | 2016-07-20 | レイショファーム ゲーエムベーハー | 線維芽細胞成長因子(fgf)のリモデリングと糖質ペグ化 |
HUE050542T2 (hu) | 2004-11-12 | 2020-12-28 | Bayer Healthcare Llc | FVIII helyspecifikus módosítása |
WO2006074467A2 (en) | 2005-01-10 | 2006-07-13 | Neose Technologies, Inc. | Glycopegylated granulocyte colony stimulating factor |
WO2006121569A2 (en) | 2005-04-08 | 2006-11-16 | Neose Technologies, Inc. | Compositions and methods for the preparation of protease resistant human growth hormone glycosylation mutants |
JP5335422B2 (ja) | 2005-06-17 | 2013-11-06 | ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト | 少なくとも1つの非天然のシステインを含んでいる操作されたタンパク質の選択的な還元および誘導体化 |
US20070105755A1 (en) | 2005-10-26 | 2007-05-10 | Neose Technologies, Inc. | One pot desialylation and glycopegylation of therapeutic peptides |
US7855279B2 (en) | 2005-09-27 | 2010-12-21 | Amunix Operating, Inc. | Unstructured recombinant polymers and uses thereof |
US20090048440A1 (en) | 2005-11-03 | 2009-02-19 | Neose Technologies, Inc. | Nucleotide Sugar Purification Using Membranes |
CN104593348A (zh) * | 2006-05-24 | 2015-05-06 | 诺沃—诺迪斯克保健股份有限公司 | 具有延长的体内半寿期的因子ix类似物 |
US20080280818A1 (en) | 2006-07-21 | 2008-11-13 | Neose Technologies, Inc. | Glycosylation of peptides via o-linked glycosylation sequences |
EP2054521A4 (en) | 2006-10-03 | 2012-12-19 | Novo Nordisk As | METHODS OF PURIFYING CONJUGATES OF POLYPEPTIDES |
EP2532369B1 (en) | 2006-12-15 | 2017-11-01 | Baxalta GmbH | Factor VIIa-(poly)sialic acid conjugate having prolonged in vivo half-life |
KR20150064246A (ko) | 2007-04-03 | 2015-06-10 | 바이오제너릭스 게엠베하 | 글리코페길화 g―csf를 이용하는 치료 방법 |
ES2551123T3 (es) | 2007-06-12 | 2015-11-16 | Ratiopharm Gmbh | Proceso mejorado para la producción de azúcares de nucleótido |
CA2704234A1 (en) * | 2007-11-09 | 2009-05-14 | Baxter International Inc. | Modified recombinant factor viii and von willebrand factor and methods of use |
RU2573587C2 (ru) | 2008-02-27 | 2016-01-20 | Ново Нордиск А/С | Конъюгированные молекулы фактора viii |
CN102112144A (zh) * | 2008-05-16 | 2011-06-29 | 拜耳医药保健有限公司 | 靶向性凝固因子及其使用方法 |
WO2009149303A1 (en) * | 2008-06-04 | 2009-12-10 | Bayer Healthcare Llc | Fviii muteins for treatment of von willebrand disease |
AU2009262476C1 (en) | 2008-06-24 | 2016-06-02 | Csl Behring Gmbh | Factor VIII, von Willebrand factor or complexes thereof with prolonged in vivo half-life |
WO2010019263A2 (en) * | 2008-08-15 | 2010-02-18 | Genzyme Corporation | Soluble flt constructs for treating cancers |
EP3437661A1 (en) * | 2008-10-17 | 2019-02-06 | Baxalta GmbH | Modified blood factors comprising a low degree of water soluble polymer |
CA2740793A1 (en) * | 2008-11-03 | 2010-06-03 | Haiyan Jiang | Method for the treatment of hemophilia |
JP2012510060A (ja) * | 2008-11-24 | 2012-04-26 | バイエル・ヘルスケア・エルエルシー | シリカをベースとする活性化部分トロンボプラスチン時間アッセイにおけるpeg化血液凝固因子の活性の測定方法 |
EP2387413A4 (en) * | 2009-01-19 | 2015-12-23 | Bayer Healthcare Llc | PROTEIN CONJUGATE WITH AN ENDOPEPTIDASE-SPLICABLE BIOPROTEKTIVES PART |
EP2393828B1 (en) | 2009-02-03 | 2016-10-12 | Amunix Operating Inc. | Extended recombinant polypeptides and compositions comprising same |
EP2398822B1 (en) * | 2009-02-19 | 2013-01-02 | Novo Nordisk A/S | Modification of factor viii |
JP5759976B2 (ja) * | 2009-03-20 | 2015-08-05 | ハンミ・サイエンス・カンパニー・リミテッド | 位置特異的な生理活性ポリペプチド結合体の調製方法 |
EP2411024A4 (en) * | 2009-03-24 | 2013-02-27 | Bayer Healthcare Llc | Variants of factor viii and associated methods of use |
US8809501B2 (en) | 2009-07-27 | 2014-08-19 | Baxter International Inc. | Nucleophilic catalysts for oxime linkage |
WO2011017055A2 (en) | 2009-07-27 | 2011-02-10 | Baxter International Inc. | Blood coagulation protein conjugates |
US8642737B2 (en) | 2010-07-26 | 2014-02-04 | Baxter International Inc. | Nucleophilic catalysts for oxime linkage |
CN104530182A (zh) | 2009-07-27 | 2015-04-22 | 利普森技术有限公司 | 非凝血蛋白的糖基多唾液酸化 |
CN102573920B (zh) | 2009-07-27 | 2015-01-14 | 利普森技术有限公司 | 非凝血蛋白的糖基多唾液酸化 |
JP5813641B2 (ja) * | 2009-08-24 | 2015-11-17 | アムニクス オペレーティング インコーポレイテッド | 凝固第ix因子組成物ならびにそれを製造および使用する方法 |
SG10201907152YA (en) | 2009-12-06 | 2019-09-27 | Bioverativ Therapeutics Inc | Factor viii-fc chimeric and hybrid polypeptides, and methods of use thereof |
WO2011075185A1 (en) | 2009-12-18 | 2011-06-23 | Oligasis | Targeted drug phosphorylcholine polymer conjugates |
EP2536753B1 (en) | 2010-02-16 | 2017-12-20 | Novo Nordisk A/S | Factor viii molecules with reduced vwf binding |
CN105664175B (zh) * | 2010-02-21 | 2019-07-23 | 拜耳医药保健有限公司 | 用于活化和缀合生物分子的方法 |
CA2795667C (en) | 2010-04-15 | 2018-09-04 | Oligasis | High molecular weight zwitterion-containing polymers |
GB201007356D0 (en) | 2010-04-30 | 2010-06-16 | Leverton Licence Holdings Ltd | Conjugated factor VIIa |
GB201007357D0 (en) * | 2010-04-30 | 2010-06-16 | Leverton Licence Holdings Ltd | Conjugated factor VIII |
WO2012006623A1 (en) * | 2010-07-09 | 2012-01-12 | Biogen Idec Hemophilia Inc. | Systems for factor viii processing and methods thereof |
US9150637B2 (en) | 2010-11-05 | 2015-10-06 | Baxalta Inc. | Variant of antihemophilic factor VIII having increased specific activity |
CA2821945A1 (en) * | 2010-12-16 | 2012-06-21 | Novo Nordisk A/S | Aqueous factor viii solution |
DK2654794T3 (da) | 2010-12-22 | 2020-06-08 | Baxalta GmbH | Materialer og fremgangsmåder til konjugering af et vandopløseligt fedtsyrederivat til et protein |
JP2014520094A (ja) | 2011-05-27 | 2014-08-21 | バクスター・インターナショナル・インコーポレイテッド | 増加した半減期を有する治療用タンパク質およびそれを調製する方法 |
PT2717898T (pt) | 2011-06-10 | 2019-05-20 | Bioverativ Therapeutics Inc | Compostos pró-coagulantes e processos para a sua utilização |
CN103930440A (zh) | 2011-07-01 | 2014-07-16 | 拜耳知识产权有限责任公司 | 松弛素融合多肽及其用途 |
AU2012282875B2 (en) | 2011-07-08 | 2016-04-21 | Bioverativ Therapeutics Inc. | Factor VIII chimeric and hybrid polypeptides, and methods of use thereof |
JP6352806B2 (ja) | 2011-09-23 | 2018-07-04 | ノヴォ ノルディスク アー/エス | 新規のグルカゴン類似体 |
KR20130049671A (ko) * | 2011-11-04 | 2013-05-14 | 한미사이언스 주식회사 | 생리활성 폴리펩타이드 결합체 제조 방법 |
AU2013204636B2 (en) | 2012-02-15 | 2016-04-14 | Bioverativ Therapeutics Inc. | Recombinant Factor VIII proteins |
US9458223B2 (en) | 2012-02-15 | 2016-10-04 | Csl Behring Gmbh | Von willebrand factor variants having improved factor VIII binding affinity |
CA2864904C (en) | 2012-02-15 | 2023-04-25 | Amunix Operating Inc. | Factor viii compositions and methods of making and using same |
EP2666782A1 (en) * | 2012-05-22 | 2013-11-27 | Imnate Sarl | Coagulation factor VIII with reduced immunogenicity. |
EP4079316A1 (en) | 2012-06-08 | 2022-10-26 | Bioverativ Therapeutics Inc. | Procoagulant compounds |
WO2014008480A2 (en) | 2012-07-06 | 2014-01-09 | Biogen Idec Ma Inc. | Cell line expressing single chain factor viii polypeptides and uses thereof |
WO2014063108A1 (en) | 2012-10-18 | 2014-04-24 | Biogen Idec Ma Inc. | Methods of using a fixed dose of a clotting factor |
EP3943102A1 (en) | 2012-10-30 | 2022-01-26 | Bioverativ Therapeutics Inc. | Methods of using fviii polypeptide |
TWI828269B (zh) | 2013-03-15 | 2024-01-01 | 美商百歐維拉提夫治療公司 | 因子ix多肽調配物 |
EA201890671A1 (ru) | 2013-03-15 | 2019-01-31 | Биовератив Терапьютикс Инк. | Препараты полипептида фактора viii |
US20160030524A1 (en) * | 2013-03-15 | 2016-02-04 | Bayer Healthcare Llc | Recombinant factor viii formulations |
PL2986313T3 (pl) | 2013-04-18 | 2019-12-31 | Novo Nordisk A/S | Stabilni, dłużej działający współagoniści receptora glp-1/glukagonu do zastosowań medycznych |
DK2796145T3 (da) | 2013-04-22 | 2018-01-29 | Csl Ltd | Et kovalent kompleks af von Willebrand-faktor og faktor VIII linket af en disulfidbro |
TW201519900A (zh) * | 2013-04-28 | 2015-06-01 | Bayer Healthcare Llc | 用於誘導對凝血因子蛋白之免疫耐受性的組成物及方法 |
EP3033098B1 (en) | 2013-08-14 | 2022-06-22 | Bioverativ Therapeutics Inc. | Recombinant factor viii proteins |
US10548953B2 (en) | 2013-08-14 | 2020-02-04 | Bioverativ Therapeutics Inc. | Factor VIII-XTEN fusions and uses thereof |
US10702608B2 (en) | 2013-09-08 | 2020-07-07 | Kodiak Sciences Inc. | Factor VIII zwitterionic polymer conjugates |
CN105848670A (zh) * | 2013-10-22 | 2016-08-10 | Dbv技术公司 | 通过诱导对血液因子的耐受治疗血友病的方法 |
US10584147B2 (en) | 2013-11-08 | 2020-03-10 | Biovertiv Therapeutics Inc. | Procoagulant fusion compound |
RU2546297C1 (ru) * | 2013-11-19 | 2015-04-10 | Федеральное государственное бюджетное учреждение "Научно-исследовательский институт фармакологии" Сибирского отделения Российской академии медицинских наук | Средство, улучшающее реологические свойства крови |
EP3082848B1 (en) | 2013-12-06 | 2023-10-18 | Bioverativ Therapeutics Inc. | Population pharmacokinetics tools and uses thereof |
KR101908074B1 (ko) | 2014-01-20 | 2018-10-15 | 옥타파마 아게 | 개선된 FVIII:C/FVIII:Ag의 비를 갖는 인자 VIII의 제조방법 |
EP3102589A1 (en) | 2014-02-04 | 2016-12-14 | Biogen MA Inc. | Use of cation-exchange chromatography in the flow-through mode to enrich post-translational modifications |
WO2015132724A1 (en) | 2014-03-05 | 2015-09-11 | Pfizer Inc. | Improved muteins of clotting factor viii |
AU2015236340B2 (en) | 2014-03-24 | 2020-02-06 | Bioverativ Therapeutics Inc. | Lyophilized factor IX formulations |
CA2944909A1 (en) * | 2014-04-04 | 2015-10-08 | Bloodworks | Routine laboratory and point-of-care (poc) testing for hemostasis |
CN106459907B (zh) | 2014-04-10 | 2020-11-06 | 拜尔健康护理有限责任公司 | 复合培养基粉末制剂和制备用于细胞培养的液体培养基的方法 |
US10570184B2 (en) | 2014-06-04 | 2020-02-25 | Novo Nordisk A/S | GLP-1/glucagon receptor co-agonists for medical use |
EP3164150B1 (en) | 2014-07-02 | 2020-11-04 | CSL Behring Lengnau AG | Modified von willebrand factor |
MA40864A (fr) | 2014-10-31 | 2017-09-05 | Biogen Ma Inc | Hypotaurine, gaba, bêta-alanine et choline pour la régulation de l'accumulation de sous-produits résiduaires dans des procédés de culture de cellules mammifères |
SG11201706659WA (en) | 2015-03-06 | 2017-09-28 | Csl Behring Recombinant Facility Ag | Modified von willebrand factor having improved half-life |
CN107810194B (zh) | 2015-05-22 | 2021-10-08 | 康诺贝林伦瑙有限公司 | 用于制备经修饰的血管性血友病因子的方法 |
CA2986626A1 (en) | 2015-05-22 | 2016-12-01 | Csl Behring Recombinant Facility Ag | Truncated von willebrand factor polypeptides for treating hemophilia |
EP3331608A4 (en) | 2015-08-03 | 2019-05-01 | Bioverativ Therapeutics Inc. | FUSION XI FUSION PROTEINS AND METHODS OF MAKING AND USING THE SAME |
US9849125B1 (en) | 2015-11-03 | 2017-12-26 | Banner Lifie Sciences LLC | Anti-overingestion dosage forms |
DK3400238T3 (da) | 2016-01-07 | 2021-07-26 | CSL Behring Lengnau AG | Muteret von willebrand faktor |
EP3400002B1 (en) | 2016-01-07 | 2022-02-02 | CSL Behring Lengnau AG | Mutated truncated von willebrand factor |
JP7235511B2 (ja) * | 2016-06-24 | 2023-03-08 | モガム・インスティテュート・フォー・バイオメディカル・リサーチ | 組換え型一本鎖fviiiおよびその化学コンジュゲート |
SG11201903954WA (en) | 2016-11-11 | 2019-05-30 | CSL Behring Lengnau AG | Truncated von willebrand factor polypeptides for extravascular administration in the treatment or prophylaxis of a blood coagulation disorder |
JP7252890B2 (ja) | 2016-11-11 | 2023-04-05 | ツェー・エス・エル・ベーリング・レングナウ・アクチエンゲゼルシャフト | 血友病を処置するための切断型フォン・ヴィルブランド因子ポリペプチド |
US11104718B2 (en) | 2016-11-16 | 2021-08-31 | Bayer Healthcare Llc | Red blood cell targeted factor VIII and method of using the same |
MX2019006446A (es) | 2016-12-02 | 2019-12-11 | Bioverativ Therapeutics Inc | Métodos para inducir tolerancia inmunológica a factores de coagulación. |
WO2018102743A1 (en) | 2016-12-02 | 2018-06-07 | Bioverativ Therapeutics Inc. | Methods of treating hemophilic arthropathy using chimeric clotting factors |
EA201991768A1 (ru) | 2017-01-31 | 2020-01-22 | Байоверетив Терапьютикс Инк. | Слитые белки на основе фактора ix и способы их получения и пути применения |
US10335375B2 (en) | 2017-05-30 | 2019-07-02 | Patheon Softgels, Inc. | Anti-overingestion abuse deterrent compositions |
KR20190086269A (ko) * | 2018-01-12 | 2019-07-22 | 재단법인 목암생명과학연구소 | 체내 지속형 재조합 당단백질 및 이의 제조방법 |
US12030925B2 (en) | 2018-05-18 | 2024-07-09 | Bioverativ Therapeutics Inc. | Methods of treating hemophilia A |
CN114786731A (zh) | 2019-10-10 | 2022-07-22 | 科达制药股份有限公司 | 治疗眼部病症的方法 |
WO2021091881A1 (en) * | 2019-11-04 | 2021-05-14 | The Trustees Of Columbia University In The City Of New York | High concentration cell penetrating caspase inhibitor conjugates compositions and methods thereof |
AU2020395323A1 (en) * | 2019-12-06 | 2022-06-30 | The Children's Hospital Of Philadelphia | Compositions and methods for modulating factor VIII function |
Family Cites Families (67)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS59172425A (ja) * | 1983-03-18 | 1984-09-29 | Nippon Chemiphar Co Ltd | 新規な血液凝固因子誘導体およびその製造法ならびにそれを含有する血液凝固促進剤 |
US7138505B1 (en) | 1984-01-12 | 2006-11-21 | Novartis Vaccines And Diagnostics, Inc. | Factor VIII:C nucleic acid molecules |
US4970300A (en) * | 1985-02-01 | 1990-11-13 | New York University | Modified factor VIII |
US5451521A (en) | 1986-05-29 | 1995-09-19 | Genetics Institute, Inc. | Procoagulant proteins |
US5422260A (en) | 1986-05-29 | 1995-06-06 | Genetics Institute, Inc. -Legal Affairs | Human factor VIII:c muteins |
IL86693A (en) | 1987-06-12 | 1994-06-24 | Stichting Centraal Lab | Proteins that have the activity IIIV of the blood, a process for their preparation that uses cells are produced through genetic engineering and pharmaceutical preparations that contain them |
EP0294910B1 (en) | 1987-06-12 | 1996-09-11 | Immuno Ag | Novel proteins with factor VIII activity, process for their preparation using genetically engineered cells and pharmaceutical compositions containing them |
US6346513B1 (en) | 1987-06-12 | 2002-02-12 | Baxter Trading Gmbh | Proteins with factor VIII activity: process for their preparation using genetically-engineered cells and pharmaceutical compositions containing them |
AU2473388A (en) * | 1987-11-16 | 1989-06-22 | Scripps Clinic And Research Foundation | Treatment of factor viii inhibitors |
US5166322A (en) | 1989-04-21 | 1992-11-24 | Genetics Institute | Cysteine added variants of interleukin-3 and chemical modifications thereof |
SE465222C5 (sv) | 1989-12-15 | 1998-02-10 | Pharmacia & Upjohn Ab | Ett rekombinant, humant faktor VIII-derivat och förfarande för dess framställning |
US5766897A (en) | 1990-06-21 | 1998-06-16 | Incyte Pharmaceuticals, Inc. | Cysteine-pegylated proteins |
US6376463B1 (en) | 1992-04-07 | 2002-04-23 | Emory University | Modified factor VIII |
US6037452A (en) | 1992-04-10 | 2000-03-14 | Alpha Therapeutic Corporation | Poly(alkylene oxide)-Factor VIII or Factor IX conjugate |
ES2154650T3 (es) | 1992-10-02 | 2001-04-16 | Genetics Inst | Composicion que comprende una formulacion con factor de coagulacion viii, procedimiento para su preparacion y uso de un tensioactivo como estabilizador. |
WO1994015625A1 (en) | 1993-01-15 | 1994-07-21 | Enzon, Inc. | Factor viii - polymeric conjugates |
SE504074C2 (sv) | 1993-07-05 | 1996-11-04 | Pharmacia Ab | Proteinberedning för subkutan, intramuskulär eller intradermal administrering |
EP0730660A4 (en) | 1993-10-29 | 1998-02-25 | Incyte Pharma Inc | CHIMEAN PROTEINE PROTEASE NEXIN-1 CONTAINING VARIANTS |
IL113010A (en) | 1994-03-31 | 1999-10-28 | Pharmacia & Upjohn Ab | Pharmaceutical formulation comprising factor viii with an activity of at least 500iu/ml and an enhancer for improved subcutaneous intramuscular or intradermal administration |
BE1008491A3 (fr) * | 1994-07-14 | 1996-05-07 | Croix Rouge De Belgique Depart | Sequence polypeptidique antigenique du facteur viii, fragments et/ou epitopes de celle-ci. |
WO1996041813A2 (en) | 1994-11-09 | 1996-12-27 | Offord Robin E | Functionalized polymers for site-specific attachment |
AU691111B2 (en) * | 1995-06-21 | 1998-05-07 | Google Technology Holdings LLC | Method and antenna for providing an omnidirectional pattern |
WO1997003195A1 (en) | 1995-07-11 | 1997-01-30 | Chiron Corporation | Novel factor viii:c polypeptide analogs with altered protease sites |
SE9503380D0 (sv) * | 1995-09-29 | 1995-09-29 | Pharmacia Ab | Protein derivatives |
AT403438B (de) | 1996-05-24 | 1998-02-25 | Immuno Ag | Pharmazeutische präparation mit faktor viii prokoagulationsaktivität und vwf-bindungsaktivität |
US6458563B1 (en) * | 1996-06-26 | 2002-10-01 | Emory University | Modified factor VIII |
BR9711009A (pt) * | 1996-08-02 | 1999-08-17 | Ortho Mcneil Pharm Inc | Polipeptidio tendo um polimero solÚvel em gua n-terminal covalentemente ligado |
CA2225189C (en) | 1997-03-06 | 2010-05-25 | Queen's University At Kingston | Canine factor viii gene, protein and methods of use |
US6753165B1 (en) * | 1999-01-14 | 2004-06-22 | Bolder Biotechnology, Inc. | Methods for making proteins containing free cysteine residues |
DE69838552T2 (de) | 1997-07-14 | 2008-05-21 | Bolder Biotechnology, Inc., Louisville | Derivate des wachstumshormons und verwandte proteine |
EP1023078A4 (en) * | 1997-10-17 | 2004-09-29 | Harvest Technologies Corp | PRECIPITATION OF A FIBRINOGEN CONCENTRATE ENRICHED WITH A GROWTH FACTOR OBTAINED FROM A PLASMA ENRICHED PLASMA |
EP0922446A1 (en) | 1997-12-03 | 1999-06-16 | Applied Research Systems Ars Holding N.V. | Solution-phase site-specific preparation of GRF-PEG conjugates |
ES2233036T3 (es) | 1998-04-27 | 2005-06-01 | Opperbas Holding B.V. | Composicion farmaceutica que comprende factor viii y liposomas neutros. |
US6759216B1 (en) | 1998-11-06 | 2004-07-06 | Emory University | Glycosylated, low antigenicity low immunogenicity factor VIII |
ATE372382T1 (de) | 1998-11-10 | 2007-09-15 | Sanquin Bloedvoorziening | Ein faktor viii-polypeptid mit faktor viii:c- aktivität |
US6136599A (en) | 1998-12-10 | 2000-10-24 | Bayer Corporation | Human hybrid host cell for mammalian gene expression |
US6358703B1 (en) | 1998-12-10 | 2002-03-19 | Bayer Corporation | Expression system for factor VIII |
NZ513077A (en) | 1999-01-14 | 2004-03-26 | Bolder Biotechnology Inc | Methods for making proteins containing free cysteine residues |
WO2000071714A2 (en) | 1999-05-24 | 2000-11-30 | The American National Red Cross | Methods of reducing factor viii clearance and compositions therefor |
EP1257295B1 (en) * | 2000-02-11 | 2009-04-15 | Bayer HealthCare LLC | Factor vii or viia-like molecules |
EP1319016A4 (en) | 2000-09-19 | 2006-05-10 | Univ Emory | MODIFIED FACTOR VIII |
CA2434097A1 (en) | 2001-01-12 | 2002-08-08 | The American National Red Cross | Methods and compositions for reducing heparan sulfate proteoglycan-mediated clearance of factor viii |
AU2002249096B2 (en) * | 2001-03-22 | 2007-06-28 | Novo Nordisk Health Care Ag | Coagulation factor VII derivatives |
WO2002096454A1 (en) | 2001-05-31 | 2002-12-05 | D. Collen Research Foundation Vzw | Recombinant molecules with reduced immunogenicity, methods and intermediates for obtaining them and their use in pharmaceutical compositions and diagnostic tools |
AU2002312660A1 (en) | 2001-05-31 | 2002-12-16 | D. Collen Research Foundation Vzw Onderwijsen Navorsing Campus Gasthuisberg K.U. Leuven | Recombinant molecules with reduced immunogenicity, methods and intermediates for obtaining them and their use in pharmaceutical compositions and diagnostic tools |
DE60234193D1 (de) | 2001-06-14 | 2009-12-10 | Scripps Research Inst | Stabilisierte faktor viii mit gentechnisch konstruierten disulfidbindungen |
AU2002337901B2 (en) | 2001-10-05 | 2008-01-17 | Expression Therapeutics Llc | Nucleic acid and amino acid sequences encoding high-level expressor factor VIII polypeptides and methods of use |
MXPA04010061A (es) | 2002-04-18 | 2004-12-13 | Merck Patent Gmbh | Factor viii modificado. |
JP4412461B2 (ja) | 2002-11-20 | 2010-02-10 | 日油株式会社 | 修飾された生体関連物質、その製造方法および中間体 |
US8003117B2 (en) | 2002-11-20 | 2011-08-23 | Nof Corporation | Polyalkylene glycol derivative and modified bio-related substance |
ES2308032T5 (es) | 2002-12-31 | 2017-04-24 | Nektar Therapeutics | Derivados poliméricos de ácido maleámico y sus bioconjugados |
US7432330B2 (en) | 2002-12-31 | 2008-10-07 | Nektar Therapeutics Al, Corporation | Hydrolytically stable maleimide-terminated polymers |
ATE485331T1 (de) | 2003-01-06 | 2010-11-15 | Nektar Therapeutics | Thiolselektive wasserlösliche polymerderivate |
PT1596887T (pt) * | 2003-02-26 | 2022-04-14 | Nektar Therapeutics | Conjugados polímero-porção fator viii |
US20050176108A1 (en) * | 2003-03-13 | 2005-08-11 | Young-Min Kim | Physiologically active polypeptide conjugate having prolonged in vivo half-life |
US20040180054A1 (en) * | 2003-03-13 | 2004-09-16 | Hanmi Pharm. Co., Ltd. | Physiologically active polypeptide conjugate having prolonged in vivo half-life |
KR20060028675A (ko) * | 2003-05-12 | 2006-03-31 | 아피맥스, 인크. | 신규한 폴리 (에틸렌 글리콜) 개질 화합물 및 그의 용도 |
MXPA05007628A (es) | 2003-05-23 | 2005-10-19 | Nektar Therapeutics Al Corp | Derivados de polimeros que tienen arreglos de atomos particulares. |
EP1502921A1 (en) | 2003-07-29 | 2005-02-02 | ZLB Behring GmbH | Recombinant mutated human factor VIII (FVIII) with improved stability |
US20050123997A1 (en) | 2003-10-30 | 2005-06-09 | Lollar John S. | Modified fVIII having reduced immunogenicity through mutagenesis of A2 and C2 epitopes |
US7211559B2 (en) | 2003-10-31 | 2007-05-01 | University Of Maryland, Baltimore | Factor VIII compositions and methods |
WO2005055930A2 (en) | 2003-12-03 | 2005-06-23 | University Of Rochester | Recombinant factor viii having increased specific activity |
WO2006027111A1 (en) | 2004-09-06 | 2006-03-16 | Zlb Behring Gmbh | Modified coagulation factor viii with enhanced stability |
HUE050542T2 (hu) | 2004-11-12 | 2020-12-28 | Bayer Healthcare Llc | FVIII helyspecifikus módosítása |
JP2008534559A (ja) | 2005-04-01 | 2008-08-28 | ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト | 血液凝固fviii類似体 |
MX2008012600A (es) * | 2006-03-31 | 2008-12-12 | Baxter Int | Factor viii pegilado. |
US7645860B2 (en) * | 2006-03-31 | 2010-01-12 | Baxter Healthcare S.A. | Factor VIII polymer conjugates |
-
2005
- 2005-11-14 HU HUE16186901A patent/HUE050542T2/hu unknown
- 2005-11-14 NO NO20200044A patent/NO345800B1/no unknown
- 2005-11-14 EP EP17170687.2A patent/EP3243834A1/en not_active Withdrawn
- 2005-11-14 CN CN201510612184.1A patent/CN105148287B/zh active Active
- 2005-11-14 NO NO20210454A patent/NO20210454A1/no unknown
- 2005-11-14 KR KR1020167023706A patent/KR101904630B1/ko active IP Right Grant
- 2005-11-14 SI SI200532308T patent/SI2363414T1/sl unknown
- 2005-11-14 WO PCT/US2005/041205 patent/WO2006053299A2/en active Search and Examination
- 2005-11-14 MX MX2007005466A patent/MX2007005466A/es active IP Right Grant
- 2005-11-14 CN CN201310125428.4A patent/CN103214569B/zh active Active
- 2005-11-14 CN CN201210455152.1A patent/CN103102406B/zh active Active
- 2005-11-14 PT PT161869011T patent/PT3130601T/pt unknown
- 2005-11-14 EP EP17166910.4A patent/EP3243833B1/en active Active
- 2005-11-14 CN CN201610201090.XA patent/CN105753968A/zh active Pending
- 2005-11-14 KR KR1020147002721A patent/KR101483917B1/ko active IP Right Grant
- 2005-11-14 PT PT58493925T patent/PT1824988T/pt unknown
- 2005-11-14 LT LTEP11153297.4T patent/LT2371856T/lt unknown
- 2005-11-14 EP EP11153300.6A patent/EP2363414B1/en active Active
- 2005-11-14 SI SI200532309T patent/SI2371856T1/sl unknown
- 2005-11-14 AU AU2005304622A patent/AU2005304622B2/en active Active
- 2005-11-14 CN CN2005800464698A patent/CN101124331B/zh active Active
- 2005-11-14 RU RU2007121517/10A patent/RU2423380C2/ru active
- 2005-11-14 CA CA2586379A patent/CA2586379C/en active Active
- 2005-11-14 EP EP11153297.4A patent/EP2371856B1/en active Active
- 2005-11-14 PL PL11153300.6T patent/PL2363414T3/pl unknown
- 2005-11-14 HU HUE11153300A patent/HUE060016T2/hu unknown
- 2005-11-14 ES ES11153300T patent/ES2930159T3/es active Active
- 2005-11-14 LT LTEP16186901.1T patent/LT3130601T/lt unknown
- 2005-11-14 DK DK11153297.4T patent/DK2371856T3/da active
- 2005-11-14 ES ES11153297T patent/ES2930143T3/es active Active
- 2005-11-14 PL PL11153297.4T patent/PL2371856T3/pl unknown
- 2005-11-14 UA UAA200706559A patent/UA95225C2/ru unknown
- 2005-11-14 BR BRPI0517795A patent/BRPI0517795B8/pt active IP Right Grant
- 2005-11-14 HU HUE11153297A patent/HUE059193T2/hu unknown
- 2005-11-14 KR KR1020127028644A patent/KR20120136413A/ko not_active Application Discontinuation
- 2005-11-14 EP EP16186901.1A patent/EP3130601B1/en active Active
- 2005-11-14 PT PT111533006T patent/PT2363414T/pt unknown
- 2005-11-14 KR KR1020147018134A patent/KR101654011B1/ko active IP Right Grant
- 2005-11-14 US US11/273,896 patent/US7632921B2/en active Active
- 2005-11-14 DK DK11153300.6T patent/DK2363414T3/da active
- 2005-11-14 MX MX2014005051A patent/MX350293B/es unknown
- 2005-11-14 ES ES16186901T patent/ES2821832T3/es active Active
- 2005-11-14 HR HRP20180481AA patent/HRP20180481B1/hr active IP Right Grant
- 2005-11-14 SI SI200532283T patent/SI3130601T1/sl unknown
- 2005-11-14 KR KR1020187027821A patent/KR20180110192A/ko not_active Application Discontinuation
- 2005-11-14 EP EP16186902.9A patent/EP3153181A1/en not_active Withdrawn
- 2005-11-14 CN CN201610838893.6A patent/CN107082806A/zh active Pending
- 2005-11-14 ES ES05849392.5T patent/ES2633916T3/es active Active
- 2005-11-14 SI SI200532158T patent/SI1824988T1/sl unknown
- 2005-11-14 KR KR1020077013131A patent/KR101243564B1/ko active Protection Beyond IP Right Term
- 2005-11-14 NZ NZ555032A patent/NZ555032A/en unknown
- 2005-11-14 PT PT111532974T patent/PT2371856T/pt unknown
- 2005-11-14 LT LTEP05849392.5T patent/LT1824988T/lt unknown
- 2005-11-14 EP EP17201672.7A patent/EP3323829B1/en active Active
- 2005-11-14 EP EP14165736.1A patent/EP2772500B1/en not_active Revoked
- 2005-11-14 EP EP05849392.5A patent/EP1824988B1/en active Active
- 2005-11-14 KR KR1020137007423A patent/KR101468345B1/ko active Protection Beyond IP Right Term
- 2005-11-14 BR BR122016022033A patent/BR122016022033B8/pt active IP Right Grant
- 2005-11-14 PL PL05849392T patent/PL1824988T3/pl unknown
- 2005-11-14 HU HUE05849392A patent/HUE033776T2/en unknown
- 2005-11-14 LT LTEP11153300.6T patent/LT2363414T/lt unknown
- 2005-11-14 DK DK05849392.5T patent/DK1824988T3/en active
- 2005-11-14 JP JP2007541405A patent/JP2008524117A/ja active Pending
-
2007
- 2007-05-01 IL IL182903A patent/IL182903A/en active IP Right Grant
- 2007-05-08 ZA ZA200703696A patent/ZA200703696B/xx unknown
- 2007-05-11 HN HN2007015683A patent/HN2007015683A/es unknown
- 2007-06-06 MA MA29972A patent/MA29663B1/fr unknown
- 2007-06-08 HR HRP20070268AA patent/HRP20070268B1/hr active IP Right Grant
- 2007-06-12 NO NO20072997A patent/NO344606B1/no unknown
-
2008
- 2008-07-15 HK HK08107795.4A patent/HK1117875A1/xx unknown
-
2009
- 2009-08-13 US US12/540,703 patent/US9364520B2/en active Active
-
2012
- 2012-10-19 JP JP2012231926A patent/JP6109523B2/ja active Active
-
2013
- 2013-01-24 US US13/748,983 patent/US9096656B2/en active Active
- 2013-08-13 HK HK13109463.4A patent/HK1182121A1/xx unknown
-
2014
- 2014-02-12 PH PH12014500352A patent/PH12014500352B1/en unknown
- 2014-05-11 IL IL232540A patent/IL232540A/en active IP Right Grant
- 2014-09-02 IL IL23443314A patent/IL234433B/en active IP Right Grant
-
2015
- 2015-02-09 JP JP2015022993A patent/JP6018238B2/ja active Active
- 2015-07-20 US US14/803,677 patent/US20160051633A1/en not_active Abandoned
-
2016
- 2016-06-13 HK HK16106727.9A patent/HK1218718A1/zh not_active IP Right Cessation
- 2016-12-02 JP JP2016234756A patent/JP6487895B2/ja active Active
- 2016-12-02 JP JP2016234757A patent/JP6559642B2/ja active Active
-
2017
- 2017-07-14 CY CY20171100753T patent/CY1119292T1/el unknown
-
2019
- 2019-05-07 HU HUS1900026C patent/HUS1900026I1/hu unknown
- 2019-05-07 FR FR19C1031C patent/FR19C1031I2/fr active Active
- 2019-05-08 LU LU00118C patent/LUC00118I2/fr unknown
- 2019-05-09 LT LTPA2019509C patent/LTC1824988I2/lt unknown
- 2019-05-10 CY CY2019024C patent/CY2019024I2/el unknown
- 2019-05-10 NL NL300989C patent/NL300989I2/nl unknown
- 2019-07-09 PH PH12019501613A patent/PH12019501613A1/en unknown
-
2020
- 2020-10-05 CY CY20201100928T patent/CY1123384T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
UA95225C2 (ru) | Модифицированный полимером фактор viii для лечения гемофилии, способ его получения | |
WO2007127440A3 (en) | Heterofunctional poly(ethylene glycol) containing acid-labile amino protecting groups and uses thereof | |
CY1121314T1 (el) | Παραγωγο ραπαμυκινης για την θεραπευτικη αντιμετωπιση του καρκινου του πνευμονα | |
WO2006047419A3 (en) | Heterobifunctional poly(ethylene glycol) and uses thereof | |
CY1119906T1 (el) | Πολυμερικες συζευξεις οπιοειδων ανταγωνιστων | |
BRPI0507680A (pt) | partìculas de fosfato de cálcio terapêuticas e métodos de fabricação e uso das mesmas | |
JP2006519238A5 (ru) | ||
WO2006103298A3 (en) | Blood coagulation fviii analogues | |
EP2309989A4 (en) | Polymerized Nanoparticles and Methods for Making and Using Them | |
TR200400295T2 (tr) | Kimyasal olarak modifiye edilmiş ensülin'in akçiğer yoluyla verilmesi | |
TR200003161T2 (tr) | Poliol-IFN-Beta konjugatları | |
MX2007012157A (es) | Micelas polimericas para suministro de farmacos. | |
EP3449946A3 (en) | Hydrophobic core carrier compositions for delivery of therapeutic agents, methods of making and using the same | |
MX2010001219A (es) | Composiciones de acido hialuronico ajustablemente reticuladas. | |
MY144221A (en) | Biocompatible polymer compositions for dual or multistaged curing. | |
WO2001058493A8 (en) | Conjugates of follicle stimulating hormones | |
EA200700435A1 (ru) | Рентгеноконтрастные полимерные стенты | |
UA82983C2 (ru) | Полимерные коньюгаты найбластина и способы их использования | |
UA93284C2 (ru) | Полиэтиленгликоль-g-csf конъюгат | |
MX2009007543A (es) | Conjugados de polimero de posaconazol y metodos de tratamiento usando los conjugados de posaconazol y polimero. | |
WO2005002516A3 (en) | Leukocyte internalized peptide-drug conjugates | |
MY173864A (en) | Site-directed modification of fviii | |
MY181129A (en) | Site-directed modification of fviii | |
MY151329A (en) | Site-directed modification of fviii | |
PT1240212E (pt) | Copolimeros reticulados a base de copolimeros policarboxilicos nao reticulados |